Access to Emergency Contraception in the Over-the-Counter Era.
After years of complex regulatory changes, levonorgestrel (LNG) emergency contraception (EC) is now approved for unrestricted sale in the United States. Timely access to EC pills is critical because they are more likely to work the sooner they are taken. This study assesses whether LNG EC is sold in accordance with current Food and Drug Administration regulations.



We distributed an online questionnaire through an EC-focused listserv for reproductive health professionals, asking data collectors to visit local stores and document product names, price, over-the-counter shelf availability, and misinformation about age restrictions. We used χ2analysis to assess bivariate associations and t tests and Wilcoxon rank-sum tests to determine differences in means.



We collected information about 220 stores. The majority (65%) stocked EC on over-the-counter shelves, although only 22% of these displayed it without a locked security enclosure. Chain pharmacies were more likely to shelf-stock EC than independent pharmacies (77% vs. 5%; p = .000), but variation existed among stores within the same chain. Among stores that were asked, 40% incorrectly reported an age restriction for non-prescription purchase of LNG EC, whereas 95% correctly reported that men can buy LNG EC. The average price of branded and generic LNG EC was $49.64 and $40.05, respectively.



Changes in the regulatory status of LNG EC have resulted in widespread confusion about how EC can be sold, and its high price contributes to access barriers. Retailers should ensure that consumers can access LNG EC quickly and easily by stocking the product on over-the-counter shelves and educating staff about current regulations.
Office of Population Research, Princeton University, Princeton, New Jersey; American Society for Emergency Contraception, Princeton, New Jersey. Electronic address: kcleland@princeton.edu.
Kelly
K
Cleland
American Society for Emergency Contraception, Princeton, New Jersey.
Jamie
J
Bass
University of Ottawa, Ottawa, Ontario, Canada.
Florida
F
Doci
University of Ottawa, Ottawa, Ontario, Canada.
Angel M
AM
Foster
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D044363:Contraception, Postcoital / Q000009:adverse effects / Q000379:methods*; D005260:Female; D006297:Health Services Accessibility / Q000331:legislation & jurisprudence*; D006801:Humans; D016912:Levonorgestrel / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D004366:Nonprescription Drugs; D012926:Social Control, Formal; D014481:United States
D004366:Nonprescription Drugs; D016912:Levonorgestrel
Contraception. 2016 May;93(5):452-4
26689477
Contraception. 2016 Feb;93(2):145-52
26363429
Lancet. 2010 Feb 13;375(9714):555-62
20116841
Obstet Gynecol. 2010 Feb;115(2 Pt 1):257-63
20093897
Contraception. 2013 Mar;87(3):300-8
23114735
Contraception. 2010 Oct;82(4):373-8
20851232
Pharmacotherapy. 2013 May;33(5):549-57
23450827
Contraception. 2008 Apr;77(4):230-3
18342644
J Adolesc Health. 2014 Jan;54(1):14-9
24360593
Hum Reprod. 2012 Jul;27(7):1994-2000
22570193
Contraception. 2014 Oct;90(4):413-5
25081865
Contraception. 1997 Dec;56(6):341-52
9494767
Sex Reprod Healthc. 2015 Mar;6(1):28-32
25637422
Hum Reprod. 2005 Jan;20(1):307-11
15567882
Lancet. 2002 Dec 7;360(9348):1803-10
12480356